TY - JOUR
T1 - Guidelines for Diagnosis of Cystic Fibrosis in Newborns through Older Adults
T2 - Cystic Fibrosis Foundation Consensus Report
AU - Farrell, Philip M.
AU - Rosenstein, Beryl J.
AU - White, Terry B.
AU - Accurso, Frank J.
AU - Castellani, Carlo
AU - Cutting, Garry R.
AU - Durie, Peter R.
AU - LeGrys, Vicky A.
AU - Massie, John
AU - Parad, Richard B.
AU - Rock, Michael J.
AU - Campbell, Preston W.
PY - 2008/8
Y1 - 2008/8
N2 - Newborn screening (NBS) for cystic fibrosis (CF) is increasingly being implemented and is soon likely to be in use throughout the United States, because early detection permits access to specialized medical care and improves outcomes. The diagnosis of CF is not always straightforward, however. The sweat chloride test remains the gold standard for CF diagnosis but does not always give a clear answer. Genotype analysis also does not always provide clarity; more than 1500 mutations have been identified in the CF transmembrane conductance regulator (CFTR) gene, not all of which result in CF. Harmful mutations in the gene can present as a spectrum of pathology ranging from sinusitis in adulthood to severe lung, pancreatic, or liver disease in infancy. Thus, CF identified postnatally must remain a clinical diagnosis. To provide guidance for the diagnosis of both infants with positive NBS results and older patients presenting with an indistinct clinical picture, the Cystic Fibrosis Foundation convened a meeting of experts in the field of CF diagnosis. Their recommendations, presented herein, involve a combination of clinical presentation, laboratory testing, and genetics to confirm a diagnosis of CF.
AB - Newborn screening (NBS) for cystic fibrosis (CF) is increasingly being implemented and is soon likely to be in use throughout the United States, because early detection permits access to specialized medical care and improves outcomes. The diagnosis of CF is not always straightforward, however. The sweat chloride test remains the gold standard for CF diagnosis but does not always give a clear answer. Genotype analysis also does not always provide clarity; more than 1500 mutations have been identified in the CF transmembrane conductance regulator (CFTR) gene, not all of which result in CF. Harmful mutations in the gene can present as a spectrum of pathology ranging from sinusitis in adulthood to severe lung, pancreatic, or liver disease in infancy. Thus, CF identified postnatally must remain a clinical diagnosis. To provide guidance for the diagnosis of both infants with positive NBS results and older patients presenting with an indistinct clinical picture, the Cystic Fibrosis Foundation convened a meeting of experts in the field of CF diagnosis. Their recommendations, presented herein, involve a combination of clinical presentation, laboratory testing, and genetics to confirm a diagnosis of CF.
UR - http://www.scopus.com/inward/record.url?scp=47049115524&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=47049115524&partnerID=8YFLogxK
U2 - 10.1016/j.jpeds.2008.05.005
DO - 10.1016/j.jpeds.2008.05.005
M3 - Article
C2 - 18639722
AN - SCOPUS:47049115524
SN - 0022-3476
VL - 153
SP - S4-S14
JO - Journal of Pediatrics
JF - Journal of Pediatrics
IS - 2
ER -